CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

BMC Immunology

Table 1 Baseline characteristics of CRC patients in Fig. 1

Group	Number of Patients	Age	Sex	TNM Stage	Location	CEA (ng/ml)	CA199 (ng/ml)	Diagnosis of Recurrence After Capecitabine Treatment
Capecitabine-sensitive	1	40	M	II	Rectum	1.9	0.6	No
	2	62	M	II	Rectum	7.83	12.44	No
	3	56	M	II	Colon	1.71	24.79	No
	4	67	M	II	Colon	1.56	0.24	No
	5	81	M	II	Rectum	4.06	19.04	No
	6	32	F	II	Rectum	4	4.02	No
	7	50	F	II	Rectum	3.31	15.57	No
	8	62	F	II	Colon	2.41	3.57	No
	9	52	M	II	Rectum	4.3	19.58	No
	10	44	F	II	Colon	1.59	11.67	No
	11	72	M	II	Colon	4.44	17.52	No
	12	21	F	II	Colon	1.25	6.48	No
	13	53	M	II	Rectum	1.06	20.42	No
	14	63	M	III	Colon	0.8	16.51	No
	15	43	M	II	Rectum	1.08	0.9	No
	16	55	F	II	Rectum	1.18	4	No
	17	46	M	II	Rectum	4.92	18.26	No
	18	69	M	II	Rectum	0.89	23	No
	19	70	F	II	Colon	4.28	8.01	No
	20	71	F	II	Colon	4.62	20.58	No
	21	64	F	II	Rectum	2.2	19.31	No
	22	72	M	II	Rectum	1.19	2.28	No
	23	61	F	II	Rectum	8.81	4.4	No
	24	62	M	II	Rectum	1.92	28	No
	25	50	F	III	Colon	3.65	16.42	No
	26	65	M	III	Rectum	3.72	15.39	No
Capecitabine-resistant	27	63	M	II	Rectum	3.16	12.47	Yes
	28	70	M	III	Colon	5.28	11.1	Yes
	29	57	M	III	Colon	14.8	31.2	Yes
	30	65	F	II	Rectum	3.65	29.4	Yes
	31	52	M	II	Rectum	4.3	30.9	Yes
	32	49	M	III	Rectum	25.8	36.8	Yes
	33	54	M	III	Rectum	16.2	36.16	Yes
	34	54	F	III	Rectum	29.74	53.2	Yes
	35	45	F	II	Rectum	14	6.7	Yes
	36	59	M	II	Colon	4.37	12.4	Yes

ISSN: 1471-2172